Alnylam Appoints New Director and Announces Board Resignations

Details

announced the resignations of two board members, Michael W. Bonney and Carolyn Bertozzi, Ph.D., effective immediately. The company also elected Stuart A. Arbuckle as a new non-employee director, effective January 5, 2026. Mr. Arbuckle brings extensive experience in biopharmaceutical commercialization and leadership. The resignations were not due to any disagreements with the company, and both departing members will continue to provide advisory services to Alnylam.

Items reported

About Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals Inc. is a pioneering biotechnology company dedicated to transforming the lives of patients through RNA interference (RNAi) therapeutics. This scientific approach allows for innovative treatments that can silence genes responsible for certain diseases, offering a unique angle on genetic therapies. Alnylam's primary focus is on developing therapeutics for genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases, contributing to redefining how these conditions are treated. The company's groundbreaking work in RNAi provides a platform for addressing otherwise untreatable or poorly managed medical conditions, positioning it as a leader in the biotechnology sector. With numerous collaborations, partnerships, and a growing pipeline of therapeutics, Alnylam plays a crucial role in advancing modern medicine and contributing to the evolving landscape of genetic therapeutics. Headquartered in Cambridge, Massachusetts, Alnylam underscores the critical intersection of innovation, medicine, and gene science in the financial and pharmaceutical markets.